Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TBPH 
Theravance Biopharma Inc (TBPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: TBPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.51% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 565.01M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 4 | Beta -0.08 | 52 Weeks Range 7.44 - 11.82 | Updated Date 07/13/2025 |
52 Weeks Range 7.44 - 11.82 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -89.38% | Operating Margin (TTM) -93.8% |
Management Effectiveness
Return on Assets (TTM) -7.98% | Return on Equity (TTM) -31.46% |
Valuation
Trailing PE - | Forward PE 555.56 | Enterprise Value 482316051 | Price to Sales(TTM) 8.66 |
Enterprise Value 482316051 | Price to Sales(TTM) 8.66 | ||
Enterprise Value to Revenue 7.39 | Enterprise Value to EBITDA -9.69 | Shares Outstanding 50001300 | Shares Floating 21666577 |
Shares Outstanding 50001300 | Shares Floating 21666577 | ||
Percent Insiders 4.48 | Percent Institutions 91.75 |
Upturn AI SWOT
Theravance Biopharma Inc
Company Overview
History and Background
Theravance Biopharma Inc. was founded in 2014, as a spin-off from Theravance, Inc. Its focus is on discovering, developing, and commercializing medicines that make a difference in the lives of patients suffering from serious illnesses. Since its inception, the company has focused on respiratory diseases and gastrointestinal disorders, achieving milestones such as FDA approvals for key products.
Core Business Areas
- Respiratory Disease: Focuses on developing inhaled medicines for respiratory diseases like COPD and asthma.
- Gastrointestinal Disorders: Concentrates on treatments for gastrointestinal conditions, exploring innovative therapies.
Leadership and Structure
Theravance Biopharma is led by a team of experienced executives in the pharmaceutical industry. The organizational structure includes research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Yupelri (revefenacin): A once-daily nebulized treatment for COPD. While precise market share data is variable and not publicly disclosed with specificity for revefenacin, it competes in a crowded COPD market against established players like Boehringer Ingelheim (Spiriva), GSK (Incruse Ellipta), and AstraZeneca (Breztri Aerosphere). Revenue numbers and detailed market share data are often proprietary and reported within broader financial statements. Competitors: Boehringer Ingelheim, GSK, AstraZeneca.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, rapid innovation, and stringent regulatory requirements. The market for respiratory and gastrointestinal drugs is substantial and growing, driven by aging populations and increased prevalence of chronic diseases.
Positioning
Theravance Biopharma is a mid-sized biopharmaceutical company specializing in respiratory and gastrointestinal disease treatments. Its competitive advantage lies in its focused approach, innovative drug development capabilities, and established presence in specific niche markets.
Total Addressable Market (TAM)
The combined TAM for respiratory and gastrointestinal disease treatments is estimated to be in the billions of dollars. Theravance Biopharma is positioned to capture a portion of this market through its existing products and pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Focused research and development in respiratory and gastrointestinal diseases
- Established commercial presence with approved products
- Experienced management team
- Partnerships with larger pharmaceutical companies
Weaknesses
- Reliance on a limited number of key products
- High research and development costs
- Competition from larger pharmaceutical companies
- Vulnerability to patent expirations
Opportunities
- Expanding into new therapeutic areas within respiratory and gastrointestinal diseases
- Developing innovative drug delivery technologies
- Strategic acquisitions of complementary businesses
- Entering emerging markets
Threats
- Regulatory hurdles and delays in drug approvals
- Competition from generic drugs and biosimilars
- Changes in healthcare reimbursement policies
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- BIIB
- VTRS
- ALNY
- AMGN
Competitive Landscape
Theravance Biopharma faces intense competition from larger, more established pharmaceutical companies. Its advantages include a focused approach and innovative drug development capabilities. Disadvantages include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the sales performance of Yupelri and milestone achievements in its drug development pipeline.
Future Projections: Future growth projections rely on successful clinical trials, new product approvals, and market penetration strategies.
Recent Initiatives: Recent initiatives include strategic collaborations, expansion of the product pipeline, and efforts to enhance commercial operations.
Summary
Theravance Biopharma is a focused biopharmaceutical company with a key product in Yupelri targeting the respiratory disease market. The company's success is highly dependent on that product and its ability to expand into new products and or new strategic directions. The company needs to continue investing in R&D and look out for regulatory changes. Theravance Biopharma's ability to grow faces external threats of competitors releasing similar products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theravance Biopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-05-16 | CEO & Director Mr. Rick E. Winningham M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://www.theravance.com |
Full time employees 97 | Website https://www.theravance.com | ||
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.